Australia's Immutep rises on 3-week high after initiation of phase-3 trial
11/12/2024 24:12
** Shares of biotechnology company Immutep IMM.AX rise as
much as 2.2% to A$0.348, their highest since Nov. 14
** Co has announced initiation of phase-3 trial for the
treatment of first-line metastatic non-small cell lung cancer
(1L NSCLC)
** Says trial will include over 150 clinical sites in over
25 countries
** Co expects to enrol the first patient in Q1 of CY2025.
** Stock has fallen 0.5% YTD, as of last close
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))